{"id":1309445,"date":"2026-05-14T08:46:18","date_gmt":"2026-05-14T03:16:18","guid":{"rendered":"https:\/\/trak.in\/stories\/?p=1309445"},"modified":"2026-05-14T08:46:31","modified_gmt":"2026-05-14T03:16:31","slug":"india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose","status":"publish","type":"post","link":"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/","title":{"rendered":"India Gets 1st Ever Alzheimer\u2019s Drug: Costs Rs 1 Lakh\/Dose"},"content":{"rendered":"\n<p>India has entered a new era in neurological treatment with the launch of its first amyloid-targeting Alzheimer\u2019s drug, Lormalzi (donanemab), by Eli Lilly and Company. The breakthrough therapy has been approved for patients with early-stage Alzheimer\u2019s disease and mild cognitive impairment.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"565\" src=\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-14-at-8.45.31-AM-1024x565.png\" alt=\"\" class=\"wp-image-1309452\" srcset=\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-14-at-8.45.31-AM-1024x565.png 1024w, https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-14-at-8.45.31-AM-300x166.png 300w, https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-14-at-8.45.31-AM-768x424.png 768w, https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-14-at-8.45.31-AM-1536x848.png 1536w, https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-14-at-8.45.31-AM-2048x1130.png 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>But the excitement comes with a massive price tag.<\/p>\n\n\n\n<p>A single 350 mg vial of Lormalzi will cost \u20b991,688 in India, making it one of the most expensive neurological therapies available in the country today.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What Makes Lormalzi Different?<\/h2>\n\n\n\n<p>Unlike traditional Alzheimer\u2019s medicines that mainly manage symptoms, donanemab is designed to target the disease process itself.<\/p>\n\n\n\n<p>The therapy works by removing amyloid plaques \u2014 protein deposits in the brain strongly associated with Alzheimer\u2019s progression. Donanemab<\/p>\n\n\n\n<p>The drug:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Is administered through monthly intravenous infusions<\/li>\n\n\n\n<li>Targets early symptomatic Alzheimer\u2019s patients<\/li>\n\n\n\n<li>Aims to slow cognitive decline rather than reverse damage already done<\/li>\n<\/ul>\n\n\n\n<p>Clinical trials showed up to 35% slowing of disease progression in some early-stage patients over 18 months.<\/p>\n\n\n\n<p>Globally, the drug is sold under the brand name Kisunla and received US FDA approval in 2024.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">India\u2019s Dementia Burden Is Rising Rapidly<\/h2>\n\n\n\n<p>The launch comes at a time when India\u2019s dementia crisis is growing fast.<\/p>\n\n\n\n<p>According to reports:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Around 8.8 million Indians currently live with dementia<\/li>\n\n\n\n<li>Cases may rise to nearly 16.9 million by 2036<\/li>\n\n\n\n<li>Alzheimer\u2019s disease accounts for the majority of dementia cases<\/li>\n<\/ul>\n\n\n\n<p>India\u2019s ageing population is expected to dramatically increase neurological disorders over the next decade.<\/p>\n\n\n\n<p>The economic burden is already enormous:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Dementia reportedly costs India over \u20b928,000 crore annually<\/li>\n\n\n\n<li>Long-term caregiving and healthcare expenses remain major challenges<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">The Biggest Problem: Affordability<\/h2>\n\n\n\n<p>Despite the medical breakthrough, experts say affordability may become the biggest obstacle.<\/p>\n\n\n\n<p>At \u20b991,688 per vial:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Monthly therapy could cost lakhs annually<\/li>\n\n\n\n<li>Treatment often continues for over a year<\/li>\n\n\n\n<li>Additional MRI scans and neurological monitoring are required<\/li>\n<\/ul>\n\n\n\n<p>That means total treatment costs could potentially exceed \u20b915-20 lakh for some patients.<\/p>\n\n\n\n<p>Eli Lilly says it will launch an \u201cAlternate Access Programme\u201d to improve affordability for eligible patients.<\/p>\n\n\n\n<p>However, experts believe access will still remain limited largely to affluent urban patients and premium hospitals.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Scientists Are Still Debating Whether These Drugs Truly Work<\/h2>\n\n\n\n<p>Interestingly, the launch is also controversial.<\/p>\n\n\n\n<p>A recent Cochrane review involving over 20,000 patients reportedly concluded that amyloid-targeting drugs like donanemab produced \u201cabsent or trivial\u201d clinical benefits despite reducing plaque buildup.<\/p>\n\n\n\n<p>Researchers also raised concerns about side effects including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Brain swelling (ARIA-E)<\/li>\n\n\n\n<li>Brain bleeding risks<\/li>\n\n\n\n<li>Need for frequent MRI monitoring<\/li>\n<\/ul>\n\n\n\n<p>However, Eli Lilly strongly rejected the review\u2019s conclusions, arguing that approved drugs should not be grouped with failed experimental molecules.<\/p>\n\n\n\n<p>This debate is now becoming one of the biggest controversies in modern neurology:<br>Does removing amyloid plaques actually translate into meaningful real-world cognitive improvement?<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Why This Launch Matters For India<\/h2>\n\n\n\n<p>Despite the debate, the launch is historically significant.<\/p>\n\n\n\n<p>India now joins a small group of countries offering advanced disease-modifying Alzheimer\u2019s therapies commercially.<\/p>\n\n\n\n<p>The move could:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Improve awareness around early dementia diagnosis<\/li>\n\n\n\n<li>Push investment into neurological healthcare<\/li>\n\n\n\n<li>Increase memory clinics and brain imaging infrastructure<\/li>\n\n\n\n<li>Accelerate India\u2019s neuro-pharma ecosystem<\/li>\n<\/ul>\n\n\n\n<p>But it also exposes a major healthcare reality:<br>India is entering an era where breakthrough medicines exist \u2014 but many remain financially inaccessible to most patients.<\/p>\n\n\n\n<p>The bigger question now is not only whether Alzheimer\u2019s can finally be slowed, but whether India\u2019s healthcare system can make such cutting-edge therapies accessible beyond a tiny elite population.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.republicworld.com\/health\/alzheimers-treatment-drug-launched-in-india-at-nearly-1-lakh-per-dose-here-s-all-you-need-to-know-2026-05-13-124121\">Image Source<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>India has entered a new era in neurological treatment with the launch of its first amyloid-targeting Alzheimer\u2019s drug, Lormalzi (donanemab), by Eli Lilly and Company. The breakthrough therapy has been approved for patients with early-stage Alzheimer\u2019s disease and mild cognitive impairment. But the excitement comes with a massive price tag. A single 350 mg vial [&hellip;]<\/p>\n","protected":false},"author":30,"featured_media":1309452,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[21],"tags":[9863],"class_list":["post-1309445","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-alzheimers-drug"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>India Gets 1st Ever Alzheimer\u2019s Drug: Costs Rs 1 Lakh\/Dose - Trak.in - Indian Business of Tech, Mobile &amp; Startups<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"India Gets 1st Ever Alzheimer\u2019s Drug: Costs Rs 1 Lakh\/Dose - Trak.in - Indian Business of Tech, Mobile &amp; Startups\" \/>\n<meta property=\"og:description\" content=\"India has entered a new era in neurological treatment with the launch of its first amyloid-targeting Alzheimer\u2019s drug, Lormalzi (donanemab), by Eli Lilly and Company. The breakthrough therapy has been approved for patients with early-stage Alzheimer\u2019s disease and mild cognitive impairment. But the excitement comes with a massive price tag. A single 350 mg vial [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/\" \/>\n<meta property=\"og:site_name\" content=\"Trak.in - Indian Business of Tech, Mobile &amp; Startups\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T03:16:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-14T03:16:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-14-at-8.45.31-AM-1024x565.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"565\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mohul Ghosh\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mohul Ghosh\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/\",\"url\":\"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/\",\"name\":\"India Gets 1st Ever Alzheimer\u2019s Drug: Costs Rs 1 Lakh\/Dose - Trak.in - Indian Business of Tech, Mobile &amp; Startups\",\"isPartOf\":{\"@id\":\"https:\/\/trak.in\/stories\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-14-at-8.45.31-AM.png\",\"datePublished\":\"2026-05-14T03:16:18+00:00\",\"dateModified\":\"2026-05-14T03:16:31+00:00\",\"author\":{\"@id\":\"https:\/\/trak.in\/stories\/#\/schema\/person\/5092a7d2906e3f3c819643435477c2a7\"},\"breadcrumb\":{\"@id\":\"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/#primaryimage\",\"url\":\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-14-at-8.45.31-AM.png\",\"contentUrl\":\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-14-at-8.45.31-AM.png\",\"width\":2276,\"height\":1256},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/trak.in\/stories\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"India Gets 1st Ever Alzheimer\u2019s Drug: Costs Rs 1 Lakh\/Dose\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/trak.in\/stories\/#website\",\"url\":\"https:\/\/trak.in\/stories\/\",\"name\":\"Trak.in - Indian Business of Tech, Mobile &amp; Startups\",\"description\":\"Trak.in is a popular Indian Business, Technology, Mobile &amp; Startup blog featuring trending News, views and analytical take on Technology, Business, Finance, Telecom, Mobile, startups &amp; Social Media Space\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/trak.in\/stories\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/trak.in\/stories\/#\/schema\/person\/5092a7d2906e3f3c819643435477c2a7\",\"name\":\"Mohul Ghosh\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/trak.in\/stories\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/66c129d83dd3f325a3b550eb1aa16891173ddfc4686361424206cd9a01311c89?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/66c129d83dd3f325a3b550eb1aa16891173ddfc4686361424206cd9a01311c89?s=96&d=mm&r=g\",\"caption\":\"Mohul Ghosh\"},\"url\":\"https:\/\/trak.in\/stories\/author\/mohul-ghosh\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"India Gets 1st Ever Alzheimer\u2019s Drug: Costs Rs 1 Lakh\/Dose - Trak.in - Indian Business of Tech, Mobile &amp; Startups","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/","og_locale":"en_US","og_type":"article","og_title":"India Gets 1st Ever Alzheimer\u2019s Drug: Costs Rs 1 Lakh\/Dose - Trak.in - Indian Business of Tech, Mobile &amp; Startups","og_description":"India has entered a new era in neurological treatment with the launch of its first amyloid-targeting Alzheimer\u2019s drug, Lormalzi (donanemab), by Eli Lilly and Company. The breakthrough therapy has been approved for patients with early-stage Alzheimer\u2019s disease and mild cognitive impairment. But the excitement comes with a massive price tag. A single 350 mg vial [&hellip;]","og_url":"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/","og_site_name":"Trak.in - Indian Business of Tech, Mobile &amp; Startups","article_published_time":"2026-05-14T03:16:18+00:00","article_modified_time":"2026-05-14T03:16:31+00:00","og_image":[{"width":1024,"height":565,"url":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-14-at-8.45.31-AM-1024x565.png","type":"image\/png"}],"author":"Mohul Ghosh","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Mohul Ghosh","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/","url":"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/","name":"India Gets 1st Ever Alzheimer\u2019s Drug: Costs Rs 1 Lakh\/Dose - Trak.in - Indian Business of Tech, Mobile &amp; Startups","isPartOf":{"@id":"https:\/\/trak.in\/stories\/#website"},"primaryImageOfPage":{"@id":"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/#primaryimage"},"image":{"@id":"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/#primaryimage"},"thumbnailUrl":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-14-at-8.45.31-AM.png","datePublished":"2026-05-14T03:16:18+00:00","dateModified":"2026-05-14T03:16:31+00:00","author":{"@id":"https:\/\/trak.in\/stories\/#\/schema\/person\/5092a7d2906e3f3c819643435477c2a7"},"breadcrumb":{"@id":"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/#primaryimage","url":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-14-at-8.45.31-AM.png","contentUrl":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-14-at-8.45.31-AM.png","width":2276,"height":1256},{"@type":"BreadcrumbList","@id":"https:\/\/trak.in\/stories\/india-gets-1st-ever-alzheimers-drug-costs-rs-1-lakh-dose\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/trak.in\/stories\/"},{"@type":"ListItem","position":2,"name":"India Gets 1st Ever Alzheimer\u2019s Drug: Costs Rs 1 Lakh\/Dose"}]},{"@type":"WebSite","@id":"https:\/\/trak.in\/stories\/#website","url":"https:\/\/trak.in\/stories\/","name":"Trak.in - Indian Business of Tech, Mobile &amp; Startups","description":"Trak.in is a popular Indian Business, Technology, Mobile &amp; Startup blog featuring trending News, views and analytical take on Technology, Business, Finance, Telecom, Mobile, startups &amp; Social Media Space","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/trak.in\/stories\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/trak.in\/stories\/#\/schema\/person\/5092a7d2906e3f3c819643435477c2a7","name":"Mohul Ghosh","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/trak.in\/stories\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/66c129d83dd3f325a3b550eb1aa16891173ddfc4686361424206cd9a01311c89?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/66c129d83dd3f325a3b550eb1aa16891173ddfc4686361424206cd9a01311c89?s=96&d=mm&r=g","caption":"Mohul Ghosh"},"url":"https:\/\/trak.in\/stories\/author\/mohul-ghosh\/"}]}},"jetpack_featured_media_url":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-14-at-8.45.31-AM.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/posts\/1309445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/users\/30"}],"replies":[{"embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/comments?post=1309445"}],"version-history":[{"count":1,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/posts\/1309445\/revisions"}],"predecessor-version":[{"id":1309453,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/posts\/1309445\/revisions\/1309453"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/media\/1309452"}],"wp:attachment":[{"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/media?parent=1309445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/categories?post=1309445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/tags?post=1309445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}